10 results about "Folch solution" patented technology

The present invention relates to a method for preparing a surgical anti-adhesion barrier film comprising the following steps:a°) a first solution, comprising an oxidized collagen is prepared,b) a polyphosphate compound is added to the solution of a) in a quantity so as to obtain a concentration of polyphosphate ranging from 0.007 to 0.7%, by weight, with respect to the total weight of the solution,c) the pH of the solution obtained in b) is adjusted to about 9 by addition of a base or to about 5.1 by addition of an acid,d) a diluted solution is prepared by adding water to solution of c),e) a first layer of solution obtained in c) is casted on an inert support,f) before complete gelation of the layer obtained in d), a second layer, of diluted solution obtained in d) is applied on top of said first layer and let to gelify,g) the gelified first and second layers are dried to obtain a film.The invention further relates to a film obtainable by such a method and to a surgical implant comprising a prosthetic fabric and such a film.

The present invention provides a cleaning composition containing alkaline electrolyzed water, which facilitates the production of a diluted solution having a predetermined pH. [Solution] A cleaning composition is provided which contains bromothymol blue, thymol blue, or phenolphthalein as a pH indicator, and alkaline electrolyzed water having a pH of 12 or higher.

To provide a hydrous fluid composition capable of maintaining anti-norovirus activity even when a lysozyme modified material is stored in water or in a low concentration polar organic solvent.SOLUTION: A hydrous fluid composition contains a lysozyme modified product and / or a salt thereof, and a cationic surfactant, the hydrous fluid composition having a fluorescence intensity, as defined in (A) below, of 5000 or more. (A) Fluorescence intensity: obtained by diluting with a phosphate buffer (pH 7.0) so that the concentration of the lysozyme modified product and / or the salt is 0.05% by mass in terms of solid content and the concentration of lysozyme modified product and / or the salt and the concentration of a phosphate is 0.2 M. The liquid obtained by adding 25 μL of a methanol solution of 8 mM 1,8-anilinonaphthalenesulfonic acid to 5 mL of the diluted solution was allowed to react at room temperature for 30 minutes, and the excitation wavelength was 390 nm (excitation bandwidth 10 nm) and the fluorescence intensity measured under the condition of excitation wavelength 390 nm (excitation bandwidth 10 nm) and fluorescence wavelength 470 nm (fluorescence bandwidth 10 nm).SELECTED DRAWING: None

To provide a measurement sample diluent capable of suppressing non-specific reactions.SOLUTION: The present invention relates to a measurement sample diluent to be used to immunologically detect an antigen contained in a sample. The measurement sample diluent contains an inorganic salt and has a dispersion coefficient D of 2400 to 3500 as calculated using the following formula (1): (Dispersion Coefficient D)=(inorganic salt concentration (mM) in the measurement sample diluent)×(pH of the measurement sample diluent) ...(1).SELECTED DRAWING: None

Provided is a kit for detecting a glycoprotein contained in a sample using an optical condensation system, the kit comprising microparticles modified by host molecules and a dilution solution for diluting the sample, in which each of the host molecules binds specifically to the glycoprotein, the dilution solution comprises a blocking agent and a buffering agent, the pH value of the dilution solution is higher than the isoelectric point of the glycoprotein, the concentration of the blocking agent is lower than a concentration at which the non-specific adsorption between the host molecules is inhibited in an environment where a light-induced force does not act on the host molecules, and the salt concentration in the dilution solution is a concentration at which the microparticles modified by the host molecules cannot be precipitated by salting out.

The invention discloses a method for detecting related substances of dapagliflozin tablets, and belongs to the technical field of medicine detection. The related substances comprise an impurity 383-1D, an impurity 383-1E, an impurity 383-1F and an impurity 383-1G, and the detection method comprises the following detection conditions: adopting a high performance liquid chromatography method, taking octadecyl silica gel as a chromatographic column, taking potassium hydrogen phosphate as a buffer solution, taking acetonitrile as a diluted solution, taking a methanol-water solution as a mobile phase A, taking an acetonitrile-water solution as a mobile phase B, carrying out gradient elution, and carrying out gradient elution to obtain the impurity 383-1D, impurity 383-1E, impurity 383-1F and impurity 383-1G. And separating the related substances of the dapagliflozin tablet, and detecting to obtain the amount of the related substances. By detecting the amount of related substances, the production of the related substances in the production process is controlled, so that the product quality of the medicine is guaranteed.

To provide processes for manufacturing a highly concentrated radionuclide complex solution which is chemically and radiochemically very stable, and to provide a pharmaceutical aqueous solution.SOLUTION: A process for manufacturing a pharmaceutical aqueous solution comprises diluting an aqueous complex solution with an aqueous dilution solution. Therein: the aqueous complex solution comprises (a) a complex comprising a radionuclide 177 Lu and a somatostatin receptor binding peptide linked to a chelator DOTA, and (b) at least one stabilizer against radiolytic degradation present at a total concentration of 15-50 mg / mL; the aqueous dilution solution comprises at least one stabilizer against radiolytic degradation; in the pharmaceutical aqueous solution, the radionuclide is present at a concentration providing a volumetric radioactivity of 250-500 MBq / mL and the stabilizer is present at a total concentration of 0.5 to 10.0 mg / mL, and the only stabilizer against radiolytic degradation, which is present in the pharmaceutical aqueous solution, is selected from ascorbic acid or a salt thereof and gentisic acid or a salt thereof.SELECTED DRAWING: None

The invention is directed to room temperature stable injectable formulations of carfilzomib or its pharmaceutically acceptable derivatives thereof in the form of ready to dilute solution and concentrates with no hemolytic potential. Further the invention is directed to a method for treating patients with relapsed or refractory multiple myeloma by administering such composition.

The invention discloses a nano compound (RAP (at) KTP (at) AuNPs) for delivering rapamycin based on targeted peptide modified gold nanoparticles as well as a preparation method and application of the nano compound. In the nano compound, the surfaces of the gold nanoparticles are modified by polyethylene glycol to form a PEG layer; the K3 targeting peptide is connected to the surface of the PEG layer through non-covalent coupling; rapamycin is loaded and wrapped in the PEG layer. SH-PEG-SH is added into the AuNPs solution, and a PEG modified AuNPs solution is obtained through a reaction; diluting the K3 targeting peptide with pure water to obtain a diluted solution, adding the diluted solution into the PEG-modified AuNPs solution, and reacting to obtain a KTP-coated AuNPs solution; the preparation method comprises the following steps: dissolving rapamycin powder by using dimethyl sulfoxide, adding the rapamycin powder into a KTP (at) AuNPs solution, and reacting to obtain the nano-composite RAP (at) KTP (at) AuNPs. The nanocomposite provided by the invention can realize efficient and accurate delivery of rapamycin, and improves the effect of treating renal fibrosis.

Provided is a kit for detecting a glycoprotein contained in a sample using an optical condensation system, the kit comprising microparticles modified by host molecules and a dilution solution for diluting the sample, in which each of the host molecules binds specifically to the glycoprotein, the dilution solution comprises a blocking agent and a buffering agent, the pH value of the dilution solution is higher than the isoelectric point of the glycoprotein, the concentration of the blocking agent is lower than a concentration at which the non-specific adsorption between the host molecules is inhibited in an environment where a light-induced force does not act on the host molecules, and the salt concentration in the dilution solution is a concentration at which the microparticles modified by the host molecules cannot be precipitated by salting out.